European equities traded in the US as American depositary receipts opened the week slightly lower late Monday morning, declining 0.17% to 1,511.94 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Novo Nordisk (NVO), which climbed 12% and 5.1%, respectively. They were followed by biotech firm Evaxion (EVAX) and biopharmaceutical company argenx (ARGX), which were up 2.8% and 1.4%, respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Grifols (GRFS), which lost 3.4% and 1.6%, respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which dropped 1.5% and 1.4%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and NuCana (NCNA), which advanced 22% and 7.4%, respectively. They were followed by biopharmaceutical company Amarin (AMRN) and software firm Endava (DAVA), which rose 3.4% and 2.5%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and pharmaceutical company Silence Therapeutics (SLN), which fell 6.5% and 1.6%, respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and mining company BHP Group (BHP), which were down 1% each.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。